Skip Navigation

Roy R. Hantgan

Cardiovascular disease is the leading cause of death in our society, and the major culprit is a blood clot formed by the unwarranted activation of the clotting cascade. While cardiologists can often restore normal blood flow through by widening the blocked artery and inserting a stent to keep it open, this approach require powerful anti-platelet drugs that can themselves cause hemorrhagic or thrombotic problems.

Research in my laboratory focuses on understanding, at the molecular level, how a class of these drugs --- integrin antagonists --- recognize their target receptor and how that interaction actually alters its structure and function. Our biophysical approach to translational research is designed to hasten the development of a new generation of safer and more effective integrin-targeted therapies.

As Director of the Macromolecular Interactions Core Laboratory, I also strive to make an array of biotechnologies “user-friendly” to my colleagues here at the medical school, at Wake Forest University, and to the wider national and international research community.

Roy Hantgan - integrin antagonists

Modeling integrin antagonists binding to their target aIIbb3 receptor. From Hantgan et al., Journal of Thrombosis and Haemostasis, 5: 542-550 (2007).

Quick Reference


Phone 336-716-4689
Fax 336-716-7671


Find A Doctor Ways to Give
Last Updated: 07-05-2016
Wake Forest Baptist Ranked among Nation’s ‘Best Hospitals’  26 Years in a Row by U.S. News & World ReportComprehensive Cancer Centers National Designation is Renewed2017-2018 Best DoctorsNursing Magnet StatusJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.

© Wake Forest Baptist Medical Center, Medical Center Boulevard, Winston-Salem, NC 27157. All Rights Reserved.